Weekender: Alkermes prepares for uncertain launch as FDA finally clears schizophrenia drug

Signup | Forward Weekender June​ 5,​ 2021 | A roundup of this week's most read stories

BROUGHT TO YOU BY — IsoPlexis Solve Research Challenges with Multi-Omics Highly multiplexed secretomics, phosphoproteomics and metabolomics enable a complete multi-omic workflow in just one week on one system. Learn more in this eBook.   Alkermes prepares for uncertain launch as FDA finally clears schizophrenia drug Lybalvi is meant to be as effective as marketed antipsychotics but without the weight gain patients typically experience. Alkermes will introduce the drug into a competitive market, however. Novartis prostate cancer drug extends survival in key test of radiopharmaceutical therapy Results from the Phase 3 trial, which Novartis plans to use to ask for approval, help validate the pharma's bet on the therapy's original developer, Endocyte. Amgen pays $400M for an eczema drug, putting faith in an old partner A deal with Kyowa Kirin gives Amgen rights to an experimental treatment aimed at an autoimmune target that has drawn interest from multiple drugmakers. Sponsored Content by Catalent Innovation in cell and gene therapy: Insights from an industry specialist Cell and gene therapies (CGTs) are poised to revolutionize the landscape of biologic drugs that treat diseases and offer hope in areas where there was previously none. MorphoSys to buy Constellation in $1.7B deal, aided by unusual funding Royalty Pharma will effectively fund MorphoSys' acquisition of the cancer biotech through a separate agreement to buy MorphoSys' shares of royalties on several marketed and experimental medicines.  An AstraZeneca, Merck drug slows the return of genetic breast cancer. Will testing speed up? Study results disclosed ahead of ASCO could make Lynparza a standard adjuvant treatment for people with an inherited form of breast cancer — as long as they know they have it.    BROUGHT TO YOU BY — Vileda Professional Reduce the risk of cross contamination in your facility! Cleaning, disinfecting and contamination control is the name of our game! We are a leader in manufacturing innovative cleaning and disinfecting systems used to clean the entire facility. We offer solutions that clean faster and more effectively while lowering your total costs! Learn more.   From Our Library Webinar - on demand Leveraging a Global Healthcare Provider Network to Acquire Insights into Real-Time Global Prescribing Trends Evidera Webinar - on demand Early Go-to-Market Considerations for Cell & Gene Therapies Guidehouse Trendline What you need to know about oncology's research boom View all resources Best of What We're Reading Evaluate Vantage Asco 2021 – financial toxicity in the spotlight Vanity Fair The Lab-Leak Theory: Inside the Fight to Uncover COVID-19’s Origins The Financial Times Vulnerable people may need vaccine boosters this year, scientists say STAT Martin Shkreli's longtime friend wants to undo his 4,000% price hike Barron's Novavax Says Data From Its U.S. Phase 3 Trial Is Coming Soon The Wall Street Journal Immunocompromised People Turn to Covid-19 Vaccine Booster Shots Suggest a story we should read Upcoming Event Overcoming Challenges in Bringing Precision Medicine Therapies to Market June 29, 2021 - June 29, 2021 | Webinar 2pm ET Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Daily Dive with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Daily Dive. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc. 1255​ 23rd Street NW, Suite 550, Washington,​ DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip